SPRB

Spruce BiosciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$120.00

+143.4% vs current

Most likely

Base case

45%

Probability

Target price

$72.00

+46.0% vs current

B-

Bear case

30%

Probability

Target price

$34.00

-31.0% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious-to-neutral. Primary sources support a real regulatory setup for TA-ERT and a defined Q4 2026 BLA target, but the stock still looks more like a monitoring situation than a clean bullish setup because financing visibility is mixed, the March 2026 Kaken termination removed non-core optionality, and the 10-K's going-concern language offsets some of the optimism from management's early-2027 runway framing [#10-K-2026-03-09] [#8-K-2026-03-20] [#PR-2026-02-18] [#PR-2026-03-09].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystAvenue tranche access and financing clarity before the next cash pinchHigh impact

The January 2026 Avenue facility funded an initial $15 million and left up to $35 million of additional capital available only if Spruce hits specified regulatory and later commercial milestones; that matters because the 2025 10-K says cash plus the initial Avenue proceeds are insufficient for at least 12 months without alternative financing or strategic alternatives, despite management also guiding to runway into early 2027 [#10-K-2026-03-09] [#PR-2026-03-09].

2026-12-31eventTA-ERT BLA submission targeted for Q4 2026High impact

Spruce said after February 2026 Type B FDA meetings that TA-ERT remains on track for a fourth-quarter 2026 BLA submission, with the agency allowing existing interventional and natural-history data to potentially support accelerated approval using CSF HS-NRE as a surrogate endpoint, but requiring drug-product PPQ work that pushed timing into Q4 2026 [#PR-2026-02-18] [#PR-2026-03-09].

2027-06-30catalystTA-ERT transition from filing story to launch-readiness storyHigh impact

Management has added commercial leadership, highlighted possible launch preparation, and noted confirmatory-study planning during BLA review, so successful regulatory execution could gradually shift SPRB from a pure filing trade toward a rare-disease launch setup; however, this remains contingent on manufacturing, review, and financing execution [#PR-2026-02-18] [#PR-2026-03-09].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology